Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy

被引:16
|
作者
Kanat, Ozkan [1 ]
Ertas, Hulya [1 ]
机构
[1] Uludag Univ, Dept Med Oncol, Fac Med, TR-16059 Gorukle, Bursa, Turkey
来源
WORLD JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 10卷 / 02期
关键词
Angiogenesis inhibition; Second-line chemotherapy; Colorectal cancer; Bevacizumab; Aflibercept; Ramucirumab; ENDOTHELIAL GROWTH-FACTOR; AFLIBERCEPT PLUS FOLFIRI; PHASE-III VELOUR; 2ND-LINE TREATMENT; FACTOR RECEPTOR-2; PLACEBO; OXALIPLATIN; SURVIVAL; COMBINATION; SAFETY;
D O I
10.5306/wjco.v10.i2.52
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Continuous inhibition of angiogenesis beyond progression is an emerging treatment concept in the management of metastatic colorectal cancer patients with prior bevacizumab exposure. Treatment options include the continuation or reintroduction of bevacizumab during the second-line chemotherapy or switching to a different antiangiogenic monoclonal antibody such as aflibercept or ramucirumab. In the selection of treatment, patient-based factors such as performance status, age, tumor burden, and tolerance and sensitivity to the firstline bevacizumab-based therapy, as well as treatment-related factors such as toxicity, efficacy, and cost, should be taken into consideration.
引用
收藏
页码:52 / 61
页数:10
相关论文
共 50 条
  • [1] Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer
    Strickler, John H.
    Hurwitz, Herbert I.
    [J]. ONCOLOGIST, 2012, 17 (04): : 513 - 524
  • [2] Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy
    Demircan, Nazim Can
    Dane, Faysal
    Ozturk, Mehmet Akif
    Babacan, Nalan Akgul
    Besiroglu, Mehmet
    Kaya, Serap
    Ercelep, Ozlem
    Tanrikulu, Eda
    Halil, Suleyman
    Koca, Sinan
    Alan, Ozkan
    Hasano, Rahip
    Yumuk, Perran Fulden
    [J]. JOURNAL OF BUON, 2019, 24 (04): : 1494 - 1500
  • [3] First-Line Therapeutic Strategies in Metastatic Colorectal Cancer
    Davies, Janine M.
    Goldberg, Richard M.
    [J]. ONCOLOGY-NEW YORK, 2008, 22 (13): : 1470 - 1479
  • [4] Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
    Scartozzi, M.
    Giampieri, R.
    Maccaroni, E.
    Del Prete, M.
    Faloppi, L.
    Bianconi, M.
    Galizia, E.
    Loretelli, C.
    Belvederesi, L.
    Bittoni, A.
    Cascinu, S.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 106 (05) : 799 - 804
  • [5] Selection of Second-line Anti-angiogenic Agents After Failure of Bevacizumab-containing First-line Chemotherapy in Metastatic Colorectal Cancer
    Boku, Narikazu
    Yamamoto, Shun
    [J]. CLINICAL COLORECTAL CANCER, 2018, 17 (04) : 251 - 254
  • [6] Bevacizumab plus XELOX as first-line therapy for patients with metastatic colorectal cancer
    Gaspar, E.
    Juarez Marroqui, A.
    Vicent, J.
    Llorca, C.
    Orts, D.
    Galan, A.
    Barrajon, E.
    Cervera Grau, J.
    Giner, V.
    Macia, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
    M Scartozzi
    R Giampieri
    E Maccaroni
    M Del Prete
    L Faloppi
    M Bianconi
    E Galizia
    C Loretelli
    L Belvederesi
    A Bittoni
    S Cascinu
    [J]. British Journal of Cancer, 2012, 106 : 799 - 804
  • [8] Novel anti-angiogenic therapeutic strategies in colorectal cancer
    Tampellini, M.
    Sonetto, C.
    Scagliotti, G. V.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (05) : 507 - 520
  • [9] Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer
    Ito, Mamoru
    Kusaba, Hitoshi
    Mukaide, Satomi
    Kishimoto, Junji
    Shimokawa, Hozumi
    Tamura, Shingo
    Makiyama, Akitaka
    Hirano, Gen
    Oda, Hisanobu
    Shirakawa, Tsuyoshi
    Komoda, Masato
    Uchino, Keita
    Tanaka, Risa
    Mitsugi, Kenji
    Esaki, Taito
    Arita, Shuji
    Ariyama, Hiroshi
    Akashi, Koichi
    Baba, Eishi
    [J]. ANTI-CANCER DRUGS, 2017, 28 (10) : 1166 - 1173
  • [10] RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first-line treatment in metastatic colorectal cancer
    Martini, G.
    Elez, E.
    Mancuso, F. M.
    Gomez Espana, M. A.
    Caratu, G.
    Matito, J.
    Argiles Martinez, G.
    Mulet Margalef, N.
    Ortiz Morales, M. J.
    Ros Montana, F. J.
    Garcia, A.
    Comas, R.
    Santos Vivas, C.
    Perez-Lopez, R.
    Nuciforo, P. G.
    Casanovas, O.
    Dienstmann, R.
    Tabernero, J.
    Aranda Aguilar, E.
    Vivancos, A.
    [J]. ANNALS OF ONCOLOGY, 2019, 30